drugset
Drugs / recombinant fowlpox-CEA(6D)/TRICOM vaccine
last change Nov 2005 re-read 2 minutes ago

recombinant fowlpox-CEA(6D)/TRICOM vaccine

Vaccine

Developed for
adult hepatocellular carcinoma · cholangiocarcinoma · colon adenocarcinoma · diffuse gastric adenocarcinoma · gallbladder adenocarcinoma · gastric intestinal type adenocarcinoma · invasive ductal breast carcinoma · male breast carcinoma
+7 more · malignant testicular germ cell tumor · mammary Paget disease · medullary thyroid gland carcinoma · ovarian endometrioid adenocarcinoma · pancreatic adenocarcinoma · rectum adenocarcinoma · salivary gland cancer
Investigated by
National Cancer Institute (NCI)

Trials 1 · a red edge is where a trial was stopped

today NCT00028496 · Ph 1
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00028496 Nov 2001 → Nov 2005 adult hepatocellular carcinoma, cholangiocarcinoma, colon adenocarcinoma, diffuse gastric adenocarcinoma +11 National Cancer Institute (NCI) Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as recombinant fowlpox-CEA(6D)/TRICOM vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00028496 ↗
Modality Vaccine “recombinant fowlpox-CEA-TRICOM vaccine” NCT00028496 ↗